Licensing for novel vaccines against Mycobacterium tuberculosis (Mtb) H37Rv

eagle-i ID

Resource Type

Properties

1. Resource Description

   "A unique and modular bioinformatic process for the discovery of potential peptide vaccines against Mycobacterium tuberculosis (Mtb) has been developed by UH researchers. This process is based on the identification of diverse Human Leukocyte Antigens (HLA) involved in the response and protection to Mtb exposure and/or infection. The antigens are selected based on the host HLA genotype, making them designer vaccine peptides. The peptides can be combined in recombinant peptides or used as a cocktail of native proteins, in order to provide adequate global coverage. In addition to vaccine development, synthetic HLA peptides can be used for diagnostic purposes. By exploiting patients’ reactivity to their personal small synthetic HLA peptide and applying empirically determined thresholds, infection versus exposure can de determined via an in vitro Interferon-gamma (IFN-γ) release assay."

2. Contact

   Park, Ann

3. Service Provided by

   Office of Technology Transfer and Economic Development (OTTED)

4. Website(s)

   http://www.otted.hawaii.edu/technology/00479/novel-vaccines-against-mycobacterium-tuberculosis-mtb-h37rv-use-small-synthetic-pep